Jazz Pharma Plc (JAZZ) Stock Price, Quote & News

Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymp...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 634 7800

Website: www.jazzpharma.com

Address:

Waterloo Exchange, Fifth Floor Waterloo Road Dublin 4, Dublin, Ireland

StockConsultant Jul. 17 at 1:04 AM

$JAZZ Jazz Pharmaceuticals stock, nice range breakout, from Stocks to Watch at https://stockconsultant.com/?JAZZ

0 · Reply

ostrich Jul. 16 at 10:19 PM

$LMND $$AABA $JZJ $JAZZ $AABB

0 · Reply

DiamondHandsBTW Jul. 16 at 12:40 PM

$JAZZ should consider acquiring $DAWN . The strategic fit is clear — Jazz is actively building a rare pediatric oncology franchise with ONC201, and $DAWN’s Ojemda (approved for pLGG) would instantly add commercial revenue, deepen glioma coverage, and bring ADC pipeline exposure. Strong synergies, clean execution. What are we waiting for?

1 · Reply

Gps_100X_ROI_Potential Jul. 15 at 3:59 PM

$SLS Vyxeos is the closest Comp to 009 treating a Very Similar Patient Population / $JAZZ published Vyxeos data - 8.0 Months of OS for FRONT LINE AML-MR at ASH in Dec. 8.0 FRONT LINE SLS009 OS of 8.9 Months is better in END Stage AML-MR than Vyxeos is for Front Line. It's Likely 009 OS will be Doubled In Front line to 18 - 20 months. . . $CPXX / Vyxeos was bought for $1.5B based on Front Line Ts-AML / AML-MR Os of 9.56 months ... the ASH Publication breaks out the AML-MRC (009 Setting). BOTTOM LINE: SLS009 is Far Better and Safer than a drug that was bought for $1.5B.

0 · Reply

Gps_100X_ROI_Potential Jul. 14 at 6:57 PM

$SLS $CPXX Was a $50M MCap when it released its Pivotal AML trial results - the market bought it up to $750M within 3 weeks, and then $JAZZ bought it for $1.5B, 5 weeks after that. SLS will be announcing PIVOTAL Trial Results for SLS009 and GPS - ANY DAY NOW.

0 · Reply

StrawberryRips Jul. 13 at 8:54 PM

$IXHL $LLY $RMD $JAZZ

3 · Reply

DDseesFTDMOASS Jul. 13 at 8:21 PM

$IXHL $JAZZ

0 · Reply

Pennystockmadness Jul. 13 at 1:36 PM

$IXHL $JAZZ i think resmed would be the perfect match. Huge pockets and buying sleep related med companies!

0 · Reply

TheGiantKiller Jul. 13 at 12:19 PM

$IXHL If Phase 2 results are positive, my prediction is that $JAZZ Pharmaceuticals buys Incannex. Jazz already markets sleep-related drugs, and has a significant presence in the global psychedelic drugs market. It's a match made in heaven. I think $JAZZ sent Dr. Lou Barbato to Incannex to be its Chief Medical Officer. Dr. Barbato had a high-level position at Jazz prior to going to Incannex last fall.

2 · Reply

Night_Owl_Biotech Jul. 12 at 3:50 PM

FY2026 revenue multiples for all 29 comm'l-stage (or almost comm'l-stage) oncology (MCs $200MM+) & all 55 non-oncology (MC's $600MM+) focused bios. $IOVA trades at the lowest FY26 revenue multiple (excl those with recent bad news like SRPT). A data read in certain lung cancers is imminent. If the data is compelling then the TIL TAM would dramatically increase. We'd guess near-term M&A candidates include: $JAZZ (JAZZ's EV is ~$3B more than market cap...multiples are based on market cap). $TARS $TGTX $AGIO We track these data points manually so we could have made a mistake. Otherwise, this is just for fun for entertainment purposes only. We have no idea who is most likely to be acquired.

3 · Reply

Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

Jul 7, 2025, 10:05 AM EDT - 10 days ago

Is JAZZ Stock Undervalued At $110?

Jul 7, 2025, 9:30 AM EDT - 10 days ago

Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor

Jul 1, 2025, 8:31 AM EDT - 16 days ago

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Jun 10, 2025, 7:05 AM EDT - 5 weeks ago

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

Jun 9, 2025, 6:00 PM EDT - 5 weeks ago

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

Jun 2, 2025, 4:05 PM EDT - 6 weeks ago

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jun 2, 2025, 12:35 PM EDT - 6 weeks ago

Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025

May 29, 2025, 7:30 AM EDT - 7 weeks ago

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025

May 21, 2025, 4:30 PM EDT - 2 months ago

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 21, 2025, 4:58 AM EDT - 2 months ago

Jazz Pharmaceuticals: One Step Forward, One Back

May 6, 2025, 11:06 PM EDT - 2 months ago

Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 2 months ago

Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Apr 30, 2025, 4:15 PM EDT - 2 months ago

Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference

Apr 25, 2025, 11:27 AM EDT - 2 months ago

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Apr 23, 2025, 4:15 PM EDT - 3 months ago

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

Apr 22, 2025, 4:15 PM EDT - 3 months ago

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

Apr 21, 2025, 4:05 PM EDT - 3 months ago

Jazz Pharmaceuticals Completes Acquisition of Chimerix

Apr 9, 2025, 3:59 PM EDT - 3 months ago

Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out

ABBV AMGN AZN BMY GSK JNJ LLY

Apr 8, 2025, 7:04 PM EDT - 3 months ago

Jazz Pharma to pay $145 million to settle narcolepsy drug antitrust case

Mar 26, 2025, 4:15 PM EDT - 4 months ago

Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 19, 2025, 7:30 AM EDT - 4 months ago

Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting

Mar 10, 2025, 10:33 PM EDT - 4 months ago

CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX

CMRX

Mar 5, 2025, 8:41 AM EST - 4 months ago

Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline

CMRX

Mar 5, 2025, 7:14 AM EST - 4 months ago

Jazz Pharmaceuticals to buy Chimerix for $935 million

CMRX

Mar 5, 2025, 7:00 AM EST - 4 months ago

Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio

CMRX

Feb 26, 2025, 3:15 PM EST - 5 months ago

Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab

Feb 25, 2025, 9:20 PM EST - 5 months ago

Jazz Pharmaceuticals plc (JAZZ) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 4:05 PM EST - 5 months ago

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance

Feb 20, 2025, 4:15 PM EST - 5 months ago

Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference

Feb 11, 2025, 4:15 PM EST - 5 months ago

Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025

Jan 22, 2025, 12:29 PM EST - 6 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN COGT ONC XBI ZYME

Jan 13, 2025, 12:56 PM EST - 6 months ago

3 Oversold Biotech Names

AVDL FOLD VKTX XBI

Dec 23, 2024, 12:53 PM EST - 7 months ago

Jazz Pharmaceuticals: Should Sing A Better Tune In 2025

Dec 17, 2024, 4:15 PM EST - 7 months ago

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 4:05 PM EST - 7 months ago

Jazz Pharmaceuticals Announces CEO Succession Plan

Dec 6, 2024, 4:05 PM EST - 7 months ago

Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting

Dec 5, 2024, 7:45 AM EST - 8 months ago

Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)

Dec 4, 2024, 4:15 PM EST - 8 months ago

Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

Dec 3, 2024, 7:49 AM EST - 8 months ago

Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

Nov 20, 2024, 7:59 PM EST - 8 months ago

Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment

Nov 20, 2024, 7:19 PM EST - 8 months ago

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Nov 19, 2024, 4:05 PM EST - 8 months ago

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

Nov 6, 2024, 7:31 PM EST - 9 months ago

Jazz Pharmaceuticals plc (JAZZ) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 6:15 PM EST - 9 months ago

Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?

Nov 6, 2024, 4:05 PM EST - 9 months ago

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results

Oct 31, 2024, 4:05 PM EDT - 9 months ago

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

Oct 23, 2024, 4:15 PM EDT - 9 months ago

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024

Oct 16, 2024, 8:39 AM EDT - 9 months ago

Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook

Oct 15, 2024, 11:50 AM EDT - 9 months ago

Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer

StockConsultant Jul. 17 at 1:04 AM

$JAZZ Jazz Pharmaceuticals stock, nice range breakout, from Stocks to Watch at https://stockconsultant.com/?JAZZ

0 · Reply

ostrich Jul. 16 at 10:19 PM

$LMND $$AABA $JZJ $JAZZ $AABB

0 · Reply

DiamondHandsBTW Jul. 16 at 12:40 PM

1 · Reply

Gps_100X_ROI_Potential Jul. 15 at 3:59 PM

0 · Reply

Gps_100X_ROI_Potential Jul. 14 at 6:57 PM

0 · Reply

StrawberryRips Jul. 13 at 8:54 PM

$IXHL $LLY $RMD $JAZZ

3 · Reply

DDseesFTDMOASS Jul. 13 at 8:21 PM

$IXHL $JAZZ

0 · Reply

Pennystockmadness Jul. 13 at 1:36 PM

$IXHL $JAZZ i think resmed would be the perfect match. Huge pockets and buying sleep related med companies!

0 · Reply

TheGiantKiller Jul. 13 at 12:19 PM

2 · Reply

Night_Owl_Biotech Jul. 12 at 3:50 PM

3 · Reply

Gps_100X_ROI_Potential Jul. 11 at 2:23 PM

$SLS AML-MRC is the worse Prognosis in AML- there are no Effective Targeted Agents. FDA Type B Minutes ... PR Next Week - LEAK Alert https://stocktwits.com/M3d79/message/620410685 $JAZZ [Vyxeos, Cpx351] is touting 8.0 months of Survival at ASCO for Newly Diagnosed AML-MRC patients. - Read the Abstract, re Aml Mutations, and you'll understand Dr. Wang, has most likely been in SLS discussions, with the FDA Explaining why SLS009/ Tambiciclib, is so Effective and Safe. - Again, Dr. Kadia and Ziedner, are on record, Saying all 009 needed for FDA Approval is 25% response Rates or Better: the Data is in at 67%, for END Stage Dying AML patients, who've Failed all Treatments, and 350% increase in OS 9 months - better than VYxeos in Front Line- and w No Serious Side Effects. - Again the Data is IN at 67% w "Confirmed Results" in the Expansion Cohorts. - News Next Week

1 · Reply

Tain0os Jul. 10 at 2:11 PM

$ABEO $JAZZ opened long positions on both. $RARE digging through all time lows -> watching for now.

0 · Reply

Qtee2 Jul. 10 at 12:51 PM

$JAZZ New CEO , Renee Gala

0 · Reply

PSTVnIXHLyoloNOW Jul. 9 at 6:18 PM

$IXHL This might have been on the $PSTV board. One of the two had like (40) 100 share trades in a row posted on the board!! Both bio stocks have massively oversold/undervalued market caps presently!! Both have the SCIENCE to become the next $JAZZ get DD ASAP $LLY $PFE

1 · Reply

Gps_100X_ROI_Potential Jul. 8 at 2:25 AM

$SLS Cpxx was a $50M mcap when it released its registrational AML trial results that confirmed efficacy and eventual fda approval ... it jumped 500% in a Day, and was up to a $750M Mcap 3 weeks later. and then Got Bought by $JAZZ for $1.5B 5 weeks after that... +1,600% in 8 weeks -- something similar, but much bigger is about to happen here.

0 · Reply

Night_Owl_Biotech Jul. 5 at 11:56 PM

$JAZZ still appears to be a potential M&A candidate with its Co-Founder & CEO since 2009 retiring at the end of this year as well as Ziihera just getting to market (nevermind Zepzelca's potential label expansion into SCLC). JAZZ's share price 1st hit $185 10 years ago in the summer of 2015 then again 4 years ago. As we've posted time & again, most commercial-stage bio M&A transactions are priced between 0.32 & 0.41X 10-year projected sales. This time we added the $BMY $CELG transaction that was priced at 0.42X CELG's 10-year revenue projection (and had a product first approved at the start of the century like JAZZ). JAZZ's FY24 gross margin is only slightly lower than CELG forecast Because JAZZ's enterprise value is about $3B higher than its market cap, share price gains from a hypothetical acquisition would not be linear to any gain in multiple. Of course we have no idea if JAZZ will ever be acquired. This is only hypothetical. This is not investment advice. $XBI

0 · Reply

BigSqueezeComing Jul. 2 at 10:26 AM

$JAZZ Jazz Pharmaceuticals Gets UBS Buy Rating After Strong ASCO 2025 Trial Results By Sheryar Siddiq | July 02, 2025, 2:46 AM

0 · Reply

Gps_100X_ROI_Potential Jul. 1 at 3:50 PM

$SLS $CPXX was a $50M nanocap that got bought by $JAZZ for $1.5B, 8 weeks after it Released Trial Data that confirmed Efficacy and FDA Approval - 9.6 Months of OS in NEWLY DIAGNOSED TS-AML/ AML-MRC patients - AML-MRC is the Same Setting as the SLS009 P2 Trial. - $JAZZ just published Further OS data at ASCO of 5.3 Months of OS for NEWLY DIAGNOSED TP53 AML. 5.3 MOS --- https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.16_suppl.6520

0 · Reply

DonCorleone77 Jun. 30 at 11:06 AM

$AVDL $JAZZ Avadel announces appeals court decision upholding FDA approval of LUMRYZ Avadel Pharmaceuticals (AVDL) announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit affirmed a prior decision of the U.S. District Court for the District of Columbia in favor of the U.S. Food and Drug Administration, FDA, in a suit brought by Jazz Pharmaceuticals (JAZZ) regarding the FDA's approval of LUMRYZTM, the first and only once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy. Following the District Court's ruling in favor of the FDA and Avadel in October 2024, which granted the FDA's Motions for Summary Judgment with respect to Jazz's complaint and denied Jazz's Motion for Summary Judgment, Jazz filed a notice of appeal to the Appeals Court. On June 27, 2025, the Appeals Court, in a unanimous panel decision, affirmed the District Court's ruling and upheld the FDA's approval of LUMRYZ.

0 · Reply

Gps_100X_ROI_Potential Jun. 27 at 5:48 PM

$SLS $JAZZ published very well recieved data for Newly Diagnosed AML-Mrc a month ago. .… 5.3 Months of OS for newly diagnosed TP53 AML was called the new Standard of Care. SLS009 End stage Patient P2 data is already in w 8.9 months, and much less tox vs the jazz data. 009 Is Right now worth 15 to 20x the current $190M mcap.

1 · Reply

Gps_100X_ROI_Potential Jun. 24 at 5:51 AM

$SLS $170M $IMGN $270M + plus phase 3 Results =‘s a $10B Buyout. and a direct comp for SLS009, $CPXX was a $50M mcap when it released its PH3 AML RESULTS for Vyxeos, it jumped 500% that day and was a $750M mcap 3 weeks later before being bought by $JAZZ for $1.5B - 5 weeks later. +1,600% in 2 months - and 009 has published better data. Something Similar but bigger is about to happen here. //

0 · Reply

swingingtech Jun. 20 at 8:00 PM

$JAZZ https://wallstreetwaves.com/jazz-august-15th-options-trading-insights-for-the-first-week/

0 · Reply

Market Cap	6.80B
Revenue (ttm)	4.07B
Net Income (ttm)	560.12M
EPS (ttm)	N/A
PE Ratio	6.62
Forward PE	54.04
Profit Margin	13.77%
Debt to Equity Ratio	1.29

Volume	359,677
Avg Vol	940,764
Day's Range	N/A - N/A
Shares Out	60.51M
Stochastic %K	98%
Beta	0.32
Analysts	Strong Sell
Price Target	$188.47